Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 08

2296P - SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways

Date

21 Oct 2023

Session

Poster session 08

Topics

Translational Research;  Primary Prevention;  Secondary Prevention/Screening

Tumour Site

Presenters

Nicola Maurea

Citation

Annals of Oncology (2023) 34 (suppl_2): S1152-S1189. 10.1016/S0923-7534(23)01927-0

Authors

N. Maurea1, I. Bisceglia2, M. Iovine3, A. Paccone4, G. Palma5, F. Bruzzese5, A. Luciano5, F. Florio6, F. Zito Marino7, R. Franco7, V. Quagliariello1

Author affiliations

  • 1 Division Of Cardiology, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT
  • 2 Division Of Cardiology, Azienda Ospedaliera San Camillo Forlanini, 00152 - Rome/IT
  • 3 Cardiology, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 4 Cardiology Department, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 5 Animal Facility, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 6 Division Of Cardiology, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, 80131 - Napoli/IT
  • 7 Pathology Unit, Universita degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2296P

Background

Doxorubicin-mediated adverse cardiovascular events are among the leading causes of morbidity and mortality in breast cancer patients. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to be of therapeutic value in patients with type 2 diabetes, chronic kidney disease, and heart failure with reduced ejection fraction, conditions that commonly coexist and are interrelated pathophysiologically.

Methods

Female C57Bl/6 mice were untreated (Sham, n=6) or treated for 10 days with doxorubicin i.p at 2.17 mg/kg (DOXO, n=6), DAPA at 12 mg/kg (DAPA, n=6) or doxorubicin combined to DAPA (DOXO-DAPA, n=6). Ejection fraction, radial and longitudinal strain were analyzed through transthoracic echocardiography (Vevo 2100). Cardiac tissue expression of NLRP3, Myd88, DAMPs (galectine 3 and calgranulinS100), pAMPK, NF-kB, and 13 chemokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL17-α, IL-18, IFN-γ, TNF-α, G-CSF, and GM-CSF) were quantified through ELISA and western blot methods.

Results

DAPA improved significantly the EF and prevented the reduction of radial and longitudinal strain after 10 days of treatment with doxorubicin. A reduced expression of NLRP3, MyD88, DAMPs and NF-kB in cardiac tissues was seen in DOXO-DAPA group compared to DOXO mice (p<0.001). Cardiac expression of IL-1β, IL-6, TNF-α, G-CSF and GM-CSF were significantly reduced after treatment with DAPA. Expression of pAMPK was strongly enhanced in DAPA-DOXO compared to DOXO group. Levels of Calgranulin S100 and galectine-3 were strongly enhanced in DOXO group; on the other hand their expression were reduced by 47.7 and 52.3% in DAPA-DOXO group vs DOXO (p<0.005). Hystology evaluation indicate reduction NF-kB expression in myocardial and renal tissue in DOXO-DAPA vs DOXO. Radial strain (RS) is 38.8% in DAPA-DOXO vs 14.1% in DOXO groups (P < 0.05); longitudinal strain (LS) is – 23.4 % in DAPA-DOXO vs – 10.5% in DOXO groups (P < 0.001)

Conclusions

In this preclinical study, DAPA is able to improve cardiac function and reduce biomarkers involved in heart failure and fibrosis. The overall picture of the study pushes the use of DAPA in prevention of cardiomyopathies induced by anthracyclines in cancer patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Istituto Nazionale Tumori-IRCCS-Fondazione G Pascale.

Funding

Ministero della Salute.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.